Trial Profile

A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered NX-019 in Patients With Advanced, EGFR Mutant Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NX-019 (Primary)
Indications Cancer; Non-small cell lung cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Nalo Therapeutics

Most Recent Events

11 Mar 2025 Planned End Date changed from 17 Oct 2027 to 1 Dec 2025.
11 Mar 2025 Planned primary completion date changed from 17 Feb 2027 to 1 Jun 2025.
11 Mar 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com